Kewaunee Scientific Q3 sales +3.3% to $69.4M; diluted EPS $0.23 vs $0.45; backlog down 17% YoY

KEWAUNEE SCIENTIFIC CORP /DE/

2026-Q3 EPS reported $2.09 revenue$210,599,000

Sales $69.4M (+3.3% YoY); pre-tax earnings $1.6M (+25.8%).
Net earnings attributable to Kewaunee $692K (diluted EPS $0.23) vs $1.35M ($0.45) prior year.
Domestic segment sales -2.0% to $50.95M; International segment sales +21.4% to $18.45M.
Order backlog $183.2M on Jan 31, 2026, down from $221.6M a year ago.
Long-term debt net of sale-leaseback reduced to $16.3M from $34.1M at fiscal year end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KEWAUNEE SCIENTIFIC CORP /DE/ reported third quarter ended January 31, 2026 results: revenue $69,399,000, net income $692,000, EPS $0.23.

Period: third quarter ended January 31, 2026
Revenue: $69,399,000
Net income: $692,000
EPS: $0.23
Result: reported results

Exact text from the filing

Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA 1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

KEWAUNEE SCIENTIFIC CORP /DE/ filing history →

Source: SEC EDGAR

accession 0000055529-26-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.